The MYDGF Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphoblast cell line, designed for targeted disruption of the MYDGF gene. This product offers a loss-of-function model for analyzing MYDGF-dependent processes in a heterogeneous B cell context, avoiding clonal biases. It is suited for bulk functional studies where population-level gene perturbation enables robust assessment of cellular outcomes.
The Raji cell line, established from an EBV-positive Burkitt lymphoma, serves as a well-characterized human B lymphoblast model with intact humoral immune properties, including immunoglobulin secretion. Its transformed state and latent EBV genome make it a gold standard for studying virus?Chost interactions and B cell malignancies. The cellular background provides a relevant system to probe growth factor signaling in lymphomagenesis and immune regulation.
MYDGF is a secreted growth factor predominantly released by myeloid cells upon exposure to inflammatory mediators such as LPS, IL-1??, and TNF-??, or under hypoxic conditions driven by HIF1??. Extracellular MYDGF engages receptors including VEGFR2 and integrin ??v??3, initiating intracellular signaling networks. Downstream, MYDGF activates the RAS?CRAF?CMEK cascade leading to ERK1/2 phosphorylation, the PI3K?CAKT?CmTOR axis promoting survival and metabolism, and JAK2?CSTAT3 transcriptional programs. These pathways converge on upregulation of Bcl-2, VEGF, and cyclin D1, which collectively enhance cell survival, angiogenesis, and cell cycle progression. Thus, MYDGF functions as a critical paracrine regulator of tissue repair and cellular resilience.
In the Raji context, MYDGF signaling potentially intersects with EBV-driven oncogenic pathways. EBV latent membrane proteins constitutively stimulate PI3K/AKT and JAK/STAT cascades, overlapping with MYDGF??s downstream effectors. Knockout of MYDGF in Raji polyclonal cells permits investigation of whether MYDGF reinforces these survival signals autonomously or influences the tumor microenvironment through secreted factors. This model enables dissection of growth factor contributions to lymphoma cell viability and the interplay between host and viral signaling in B cell transformation.
Researchers can employ these cells in various assay platforms. Western blotting and RT-qPCR confirm target disruption and pathway modulation. Flow cytometric analysis of apoptosis and proliferation markers, together with cell proliferation and colony formation assays, quantifies MYDGF dependency. ELISA measures altered cytokine secretion. Xenograft tumor models assess in vivo growth effects. Additionally, drug sensitivity screens can identify inhibitors of MYDGF-related pathways. These applications facilitate studies in B cell lymphoma biology, tumor microenvironment interactions, immune evasion, and EBV-associated oncogenesis. For further details or custom requests, please contact Ascent Research.
